Small-to-mid-sized pharmaceutical companies are an important customer base for suppliers, CDMOs, and CMOs. Learn about key trends and first-hand experience from pharmaceutical companies on key issues impacting the customer–supplier relationship. For speakers and topics, click on the session details below.
C-suite, senior, and mid-level executives from contract service providers and suppliers of products and services used in chemical, pharmaceutical, and biopharmaceutical development and manufacturing, packaging, and the related supply chain. Key job functions of attendees include: Business Development, Sales, Marketing, Project Management, Development, and Manufacturing.
Please note: To deliver targeted insight and create a comfortable environment for attendees, DCAT and its planning committees respectfully require that Suppliers’ Track attendees only be from contract service providers and suppliers. DCAT reserves the right to reassign registrants to the appropriate track.
Heading to the Hyatt the evening before?
Join us the night before the forums on June 25th from 8:00-10:00PM for our Pre-Program Welcome & Networking Reception at the Glass Woods Tavern on the first floor of the Hyatt Regency Hotel!
Speaker: Brian Doyle, Managing Director and Partner, William Blair & Company
Speaker: Rick Panicucci, Senior Vice President, Chemistry, Manufacturing and Controls (CMC), QED Therapeutics
Speaker: Simon McGurk, PhD, Executive Director, Drug Product Development and Analytical Development, TESARO, Inc.
Featuring co-presentations of pharmaceutical companies and suppliers, this session offers candid perspectives on real-world challenges that arise in a campaign and how partners resolved those issues, including:
Cost-Competitive Manufacturing through Collaboration and Relationship Management
Merck’s antibiotic portfolio requires compliant, cost-competitive manufacturing of beta-lactam intermediates that are hard to source due to stringent segregation requirements. Merck looked early on, beyond loss of exclusivity, to create a cost-competitive manufacturing center of excellence that also provided regulatory, quality, and environmental, health, and safety (EHS) compliance. Merck and Asymchem will look back and share the details of this journey, from reconfiguring a CMO site into a beta-lactam facility and the initial challenges to the evolution of collaboration and relationship management that expanded this initial opportunity into a future collaboration.
Partnering for Security of Supply
The success of a business’s global supply chain depends on managing and mitigating risks and working with partners to achieve security of supply. Teva Pharmaceuticals and Amcor will provide lessons learned on how they resolved a potential disruption in supply of packaging materials using an advanced sourcing approach with upstream suppliers. They will discuss how they addressed short-and longer-term supply needs, enabled qualification of alternative product choices, and managed inventory and cost.
Launching Innovative Oncology Drugs Through External Collaboration: Specialized Technologies and Accelerated Timelines
Oncology is the largest therapeutic market sector in the global pharmaceutical industry, and it presents opportunities for promising drug candidates and commercial products. Those opportunities, however, also can come with unique challenges in drug-substance development and manufacturing, especially for a biotech company that relies on contract development and manufacturing organizations (CDMO). TESARO, Inc., and WuXi STA will provide their experience in developing a small-molecule oncology drug and the approaches they took for a project requiring specialized technologies in potency manufacturing under rapid timelines from development to commercial launch.
In an era when chief procurement officers (CPOs) are trying to unlock the next gear of productivity, how can Big Data capabilities be used to transform procurement and sourcing practices? Gain first-hand insight from a CPO with experience gained from Fortune 500 companies Biogen, Kraft, and Kellogg’s on how Big Data tools and a new methodology, “constraintless bidding,” can be used to drive savings and value. Learn how a robust Big Data analytics strategy is a gateway to transition “analog” procurement practices into “digital” practices by enabling the application of robotic process automation (RPA), machine learning, natural language processing, and artificial intelligence.
Speaker: Wendell P. Weeks, Chairman and CEO, Corning Incorporated
What does it take to bring supplier-enabled innovation to fruition? Learn of the key success factors to build truly collaborative partnerships and to execute a winning strategy.
Wendell P. Weeks, Chairman and Chief Executive Officer (CEO) of Corning Incorporated, will share his insights and lessons learned from his 35-year career with Corning with examples from the company’s work with partners such as Apple Inc., Samsung Electronics Co., Ford Motor Company, Verizon, Sharp Corporation and most recently, Pfizer, Inc. and Merck & Co., Inc.
In 2017, Corning announced a planned investment of $4 billion with the introduction of a new product, Corning Valor Glass, for parenteral drug packaging that was the outgrowth of its partnership with Merck & Co., Inc. and Pfizer, Inc., which provided insights on pharmaceutical formulation and manufacturing processes.
As a result of the companies’ common goal to improve glass quality and promising results from initial testing, Corning is making an initial investment of $500 million as the first part of planned investment of $4 billion. Mr. Weeks will discuss the structure and governance of the collaboration and how the companies partnered in new product development, including addressing ways to lower systems costs and improve manufacturing efficiency, in order to bring the product to market.
Click here for full bio.
Simon McGurk, PhD
Executive Director, Drug Product Development and Analytical Development
Simon McGurk, PhD, is Executive Director of Drug Product Development and Analytical Development at TESARO, Inc., a Waltham, Massachusetts-based biopharmaceutical company. In this role, he is responsible for the development and validation of TESARO’s pipeline of small- and large-molecule drug products using a global network of contract development and manufacturing organizations. During his 19 years in the pharmaceutical industry, he has been involved in the approval of over 16 drug products in the areas of oncology, cardiovascular, pain management, immunotherapies, and antibacterial therapies.
Dr. McGurk earned his undergraduate degree from the School of Engineering at the University of Liverpool, UK and his PhD from the School of Pharmacy at the University of Nottingham, UK.
Managing Director and Partner
William Blair & Company
Brian Doyle is Managing Director and a Partner at William Blair & Company, where he leads its pharmaceutical services investment-banking practice. Prior to joining William Blair & Company in 2000, he spent three years at Abbott Laboratories working in a variety of finance and accounting positions and worked for four years at Price Waterhouse LLP in the audit and financial consulting practice focused primarily on middle-market companies. He has a bachelor’s of science in accounting from Villanova and an MBA from the Harvard Business School. He also is a certified public accountant.
Senior Vice President, Chemistry, Manufacturing and Controls (CMC)
Rick Panicucci is Senior Vice President of CMC (Chemistry, Manufacturing and Controls) for QED Therapeutics, a Bridge Bio company. Prior to Bridge Bio, he served as the Vice President of Pharmaceutical Development Services at WuXi STA. In this capacity, he provided scientific leadership from developability, formulation development, and GMP manufacturing.
Previously, Mr. Panicucci was the Global Head of Chemical and Pharmaceutical Profiling at Novartis from 2004 to 2015. His responsibilities included analytics, solid-state chemistry, and formulation development of all small-molecule therapeutics. He also helped develop novel drug-delivery technologies for small molecules and large molecules, including siRNA. He has also led groups in research and development at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb.
James Gage, PhD
Chief Scientific Officer
James Gage, PhD, is the Head of Research and Development and Chief Scientific Officer for Asymchem, where he manages implementation of commercial processes in Asymchem’s manufacturing facilities and leads efforts to expand the company’s capabilities through development and application of new technology.
He has 27 years of experience in process chemistry and other aspects of pharmaceutical chemistry, manufacturing and controls (CMC). Prior to joining Asymchem in early 2006, Dr. Gage worked for Pfizer and Upjohn for over 14 years. He earned a PhD in chemistry with Professor David Evans at Harvard University.
Senior Vice President and Chief Procurement Officer
Walter Charles is the Chief Procurement Officer (CPO) at Allergan, where his global procurement teams support the purchase of billions of dollars a year of products and services supporting research & development, manufacturing, marketing, legal, capital, information technology, plant operations, travel, and general and administrative services. Prior to joining Allergan, he held CPO roles at companies such as Biogen, Kraft Foods, Kellogg’s, Johnson & Johnson Consumer Supply Chain, and Cordis (one of Johnson & Johnson’s former medical devices companies). As such, he has the unique perspective of serving on supply-chain leadership teams and leading procurement transformations across multiple industries, including biotechnology, consumer packaged goods, pharmaceutical, and medical devices.
Tangqing Li, PhD
Executive Director of Project Management
STA Pharmaceutical, a WuXi AppTec company
Tangqing Li is Executive Director of Project Management, STA Pharmaceutical, a WuXi AppTec company, where he heads US-based project management. He has extensive knowledge and experience in both early- and late-phase drug development, including process validations, program management, and regulatory filings. He earned his PhD in organic chemistry at Rice University and his bachelor’s of science in chemistry at Peking University.
Prashant S. Savle, PhD
Director, Commercialization Projects, Global Procurement
Merck & Co., Inc.
Prashant S. Savle, PhD, is Director, Commercialization Projects, Global Procurement, Merck & Co., Inc., where his responsibilities include commercialization of drug substances and non-sterile and sterile drug-product formulations.
He has over 20 years of technical, business, and program-management experience, including global experience in technology development and scale-up, research and development, and clinical active pharmaceutical ingredient, sourcing, process validation, and commercial contract management. He brings a unique blend of experience from buyer-side sourcing and as a project manager with large contract manufacturing organizations, such as Rhodia ChiRex, Avecia Biotechnology, Inc. and Sigma-Aldrich Fine Chemicals.
Dr. Savle has supported drug-substance manufacturing projects spanning small molecules, antibiotics, bioconjugates, peptides, and oligonucleotides and has been a part of launch teams that have obtained 20 new drug approvals to date. He has a PhD in organic chemistry from the University of Cambridge, UK.
Daniel J. Hoey
Senior Vice President, Global Supply Chain, Global Operations
Daniel J. Hoey is Senior Vice President, Global Supply Chain, Global Operations, Teva Pharmaceuticals, where he has responsibility for ensuring the highest levels of customer service for a fully integrated global manufacturing and supply-chain organization that supports Teva’s global operations network, which delivers patient-centric healthcare solutions to millions of patients in more than 100 markets.
He has nearly 30 years of experience in the global pharmaceutical industry as a senior leader specializing in supply-chain management, manufacturing, and business operations. Previously, he led Global Manufacturing and Supply Chain for Teva Active Pharmaceutical Ingredients and held oversight responsibility for Teva’s biologics operations.
Prior to joining Teva in 2016, Mr. Hoey held senior leadership roles for global operations at Merck & Co., Inc., where he served in a variety of technical, supply chain, and contract manufacturing roles during the course of his 27 years there.
Mr. Hoey earned a bachelor’s of science in chemical engineering from Michigan State University. In addition, he holds an Executive Belt in Lean/Six Sigma and is also certified in change-execution methodology and behavior-based performance improvement.
Site Head, Procurement
Graham Degn is Site Head, Procurement, Teva Pharmaceuticals. He is based in Salt Lake City, Utah and is the Procurement Lead for Teva sites in Salt Lake City and Irvine, California. He has worked in the supply-chain /procurement side of pharmaceutical manufacturing for 13 years. During this time, he has been involved with numerous product launches, ranging in all forms of drug-delivery methods. He has a degree in business and has professional certifications from APICS and ASQ.
Vice President, Sales, Global Pharma
Arturo (Art) Castro is Vice President, Sales, Global Pharma at Amcor, where together with his team, he sets the global strategy and works to increase partnership with Amcor’s top global pharma customers.
He has been with Amcor for over 25 years with roles of increasing responsibility. Prior to his current role as Vice President Sales, Global Pharma, Mr. Castro was Vice President and General Manager for the Food & Pharmaceutical Americas business. For the last 20-plus years, Mr. Castro has been working on the 5P’s of marketing (product, place, price, promotion and packaging). He has been focused on helping customers grow and prosper globally through the application of novel packaging.
Prior to joining Amcor, Mr. Castro was a sergeant with the United States Marine Corps. He holds a bachelor’s of science in business, management and marketing. Originally from California, he is currently based in Zurich, Switzerland.
George Wu, PhD
Vice President and Presidential Fellow, Pharmaceutical Sciences
George Wu is Vice President and Presidential Fellow, Pharmaceutical Sciences, TESARO, an oncology-focused biopharmaceutical company. Dr. Wu has 29 years of experience and broad knowledge in pharmaceutical research and development covering new compound recommendation, early- and late-stage development, process transfer and validation, regulatory submission and approval, product launch, and lifecycle management at major pharmaceutical and biopharmaceutical companies.
Prior to joining TESARO, Dr. Wu worked for Merck & Co., Inc. and Schering-Plough, as a Distinguished Fellow—Senior Scientific Director, for 22 years. He has more than 70 publications and patents and has won various awards. Dr. Wu earned his PhD degree in chemistry under the direction of Professor Richard F. Heck at the University of Delaware and carried out his postdoctoral research with Professor Ei-ichi Negishi at Purdue University.
Heading to the Hyatt the evening before?
Join us June 25th from 8:00-10:00PM for our Pre-Program Welcome & Networking Reception at the Glass Woods Tavern on the first floor!
Schedule for June 26th:
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.